Research ArticleOriginal Article
Open Access

Impact of vaccination on morbidity and mortality in adults hospitalized with COVID-19 during the omicron wave in the Jazan Region, Saudi Arabia

Mohammed Y. Elamin, Yahya A. Maslamani, Feras A. Alsheikh, Mohsen A. Sailah, Mussab A. Samm, Ahmed M. Motanbk, Yehya M. Hejri, Anwar A. Alameer, Osama H. Khalid, Abdu A. Dahlan and Ibrahim M. Gosadi
Saudi Medical Journal February 2024, 45 (2) 179-187; DOI: https://doi.org/10.15537/smj.2024.45.2.20230530

References

  1. 1.↵
    WHO. Novel coronavirus (2019-nCoV): situation report-8. [Updated 2020; accessed 2023 Jun 10]. Available from: https://iris.who.int/handle/10665/330773
  2. 2.↵
    1. Gates B
    . Responding to covid-19 - a once-in-a-century pandemic? N Engl J Med 2020; 382: 1677-1679.
    OpenUrlPubMed
  3. 3.↵
    WHO. Novel coronavirus (2019-nCoV): situation report, 11. [Updated 2020; accessed 2023 Jun 9]. Available from: https://iris.who.int/handle/10665/330776
  4. 4.↵
    WHO. COVID-19 dashboard. [Updated 2023; accessed 2023 Jun 10]. Available from: https://data.who.int/dashboards/covid19/cases?n=c
  5. 5.↵
    1. Huang H,
    2. Cai S,
    3. Li Y,
    4. Li Y,
    5. Fan Y,
    6. Li L, et al.
    Prognostic factors for COVID-19 pneumonia progression to severe symptoms based on earlier clinical features: a retrospective analysis. Front Med (Lausanne) 2020; 7: 557453.
    OpenUrl
  6. 6.↵
    1. Chen N,
    2. Zhou M,
    3. Dong X,
    4. Qu J,
    5. Gong F,
    6. Han Y, et al.
    Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507-513.
    OpenUrlCrossRefPubMed
  7. 7.
    1. Huang C,
    2. Wang Y,
    3. Li X,
    4. Ren L,
    5. Zhao J,
    6. Hu Y, et al.
    Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Lai CC,
    2. Shih TP,
    3. Ko WC,
    4. Tang HJ,
    5. Hsueh PR
    . Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020; 55: 105924.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Xing C,
    2. Zhang R
    . COVID-19 in China: responses, challenges and implications for the health system. Healthcare (Basel) 2021; 9: 82.
    OpenUrl
  10. 10.↵
    1. Tallei TE,
    2. Alhumaid S,
    3. AlMusa Z,
    4. Fatimawali, Kusumawaty D,
    5. Alynbiawi A, et al.
    Update on the omicron sub-variants BA.4 and BA.5. Rev Med Virol 2023; 33: e2391.
    OpenUrl
  11. 11.↵
    CDC. Benefits of getting a COVID-19 vaccine. [Updated 2023; accessed 2023 Jun 9]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html
  12. 12.↵
    1. Cele S,
    2. Jackson L,
    3. Khoury DS,
    4. Khan K,
    5. Moyo-Gwete T,
    6. Tegally H, et al.
    Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 2022; 602: 654-656.
    OpenUrlPubMed
  13. 13.
    1. Vikse EL,
    2. Fossum E,
    3. Erdal MS,
    4. Hungnes O,
    5. Bragstad K
    . Poor neutralizing antibody responses against SARS-CoV-2 omicron BQ.1.1 and XBB in Norway in October 2022. Influenza Other Respir Viruses 2023; 17: e13144.
    OpenUrl
  14. 14.
    1. Liu L,
    2. Iketani S,
    3. Guo Y,
    4. Chan JF,
    5. Wang M,
    6. Liu L, et al.
    Striking antibody evasion manifested by the omicron variant of SARS-CoV-2. Nature 2022; 602: 676-681.
    OpenUrlCrossRefPubMed
  15. 15.
    1. Planas D,
    2. Saunders N,
    3. Maes P,
    4. Guivel-Benhassine F,
    5. Planchais C,
    6. Buchrieser J, et al.
    Considerable escape of SARS-CoV-2 omicron to antibody neutralization. Nature 2022; 602: 671-675.
    OpenUrlPubMed
  16. 16.↵
    1. Chi X,
    2. Guo Y,
    3. Zhang G,
    4. Sun H,
    5. Zhang J,
    6. Li M, et al.
    Broadly neutralizing antibodies against omicron-included SARS-CoV-2 variants induced by vaccination. Signal Transduct Target Ther 2022; 7: 139.
    OpenUrl
  17. 17.↵
    1. Rees EM,
    2. Nightingale ES,
    3. Jafari Y,
    4. Waterlow NR,
    5. Clifford S,
    6. B Pearson CA, et al.
    COVID-19 length of hospital stay: a systematic review and data synthesis. BMC Med 2020; 18: 270.
    OpenUrlPubMed
  18. 18.↵
    Public Health Authority. Coronavirus disease: COVID-19 guidelines V 3.1. [Updated 2023; accessed 2023 Jun 26]. Available from: https://covid19.cdc.gov.sa/wp-content/uploads/2023/04/V3.1COVID-19-Coronavirus-Disease-Guidelinesfinal-editionApr4-en.pdf
  19. 19.↵
    1. Alwafi H,
    2. Naser AY,
    3. Qanash S,
    4. Brinji AS,
    5. Ghazawi MA,
    6. Alotaibi B, et al.
    Predictors of length of hospital stay, mortality, and outcomes among hospitalised COVID-19 patients in Saudi Arabia: a cross-sectional study. J Multidiscip Healthc 2021; 14: 839-852.
    OpenUrl
  20. 20.↵
    1. Nachega JB,
    2. Ishoso DK,
    3. Otokoye JO,
    4. Hermans MP,
    5. Machekano RN,
    6. Sam-Agudu NA, et al.
    Clinical characteristics and outcomes of patients hospitalized for COVID-19 in Africa: early insights from the Democratic Republic of the Congo. Am J Trop Med Hyg 2020; 103: 2419-2428.
    OpenUrlPubMed
  21. 21.↵
    1. Al-Ghamdi MA,
    2. Al-Raddadi RM,
    3. Ramadan IK,
    4. Mirza AA,
    5. Alsaab HA,
    6. Alobaidi HF, et al.
    Survival, mortality, and related comorbidities among COVID-19 patients in Saudi Arabia: a hospital-based retrospective cohort study. Saudi Med J 2022; 43: 915-926.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Karyono DR,
    2. Wicaksana AL
    . Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. [Updated 2020; accessed 2023 Jun 9] Available from: https://jurnal.ugm.ac.id/jcoemph/article/view/57325
  23. 23.↵
    1. Djaharuddin I,
    2. Munawwarah S,
    3. Nurulita A,
    4. Ilyas M,
    5. Tabri NA,
    6. Lihawa N
    . Comorbidities and mortality in COVID-19 patients. Gac Sanit 2021; 35: S530-S532.
    OpenUrl
  24. 24.↵
    1. Grasselli G,
    2. Zangrillo A,
    3. Zanella A,
    4. Antonelli M,
    5. Cabrini L,
    6. Castelli A, et al.
    Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020; 323: 1574-1581.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Mhawish H,
    2. Mady A,
    3. Alaklobi F,
    4. Aletreby W,
    5. Asad T,
    6. Alodat M, et al.
    Comparison of severity of immunized versus non-immunized COVID-19 patients admitted to ICU: a prospective observational study. Ann Med Surg (Lond) 2021; 71: 102951.
    OpenUrl
  26. 26.↵
    1. Dagan N,
    2. Barda N,
    3. Kepten E,
    4. Miron O,
    5. Perchik S,
    6. Katz MA, et al.
    BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021; 384: 1412-1423.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Vasileiou E,
    2. Simpson CR,
    3. Shi T,
    4. Kerr S,
    5. Agrawal U,
    6. Akbari A, et al.
    Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet 2021; 397: 1646-1657.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Tenforde MW,
    2. Self WH,
    3. Adams K,
    4. Gaglani M,
    5. Ginde AA,
    6. McNeal T, et al.
    Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA 2021; 326: 2043-2054.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Grapsa E,
    2. Adamos G,
    3. Andrianopoulos I,
    4. Tsolaki V,
    5. Giannakoulis VG,
    6. Karavidas N, et al.
    Association between vaccination status and mortality among intubated patients with COVID-19-related acute respiratory distress syndrome. JAMA Netw Open 2022; 5: e2235219.
    OpenUrl
  30. 30.↵
    1. Bubar KM,
    2. Reinholt K,
    3. Kissler SM,
    4. Lipsitch M,
    5. Cobey S,
    6. Grad YH, et al.
    Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science 2021; 371: 916-921.
    OpenUrlAbstract/FREE Full Text
  31. 31.
    1. Liu XQ,
    2. Xue S,
    3. Xu JB,
    4. Ge H,
    5. Mao Q,
    6. Xu XH, et al.
    Clinical characteristics and related risk factors of disease severity in 101 COVID-19 patients hospitalized in Wuhan, China. Acta Pharmacol Sin 2022; 43: 64-75.
    OpenUrl
  32. 32.↵
    1. Chidambaram V,
    2. Tun NL,
    3. Haque WZ,
    4. Majella MG,
    5. Sivakumar RK,
    6. Kumar A, et al.
    Factors associated with disease severity and mortality among patients with COVID-19: a systematic review and meta-analysis. PLoS One 2020; 15: e0241541.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Bowe B,
    2. Xie Y,
    3. Al-Aly Z
    . Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med 2022; 28: 2398-2405.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Mensah AA,
    2. Lacy J,
    3. Stowe J,
    4. Seghezzo G,
    5. Sachdeva R,
    6. Simmons R, et al.
    Disease severity during SARS-COV-2 reinfection: a nationwide study. J Infect 2022; 84: 542-550.
    OpenUrlCrossRef
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords